· ´ëÇ¥Á¦Ç° | ´ÙÀß·º½º(Darzalex) |
---|---|
· ȸ»ç¼Ò°³ | Çѱ¹¾á¼¾ - https://www.janssen.com/korea/ |
· ´ëÇ¥Á¦Ç° | Á¶½ºÆÄŸ¢çÁ¤ (XOSPATA) |
---|---|
· ȸ»ç¼Ò°³ | Çѱ¹¾Æ½ºÅÚ¶ó½ºÁ¦¾à - www.astellas.com/kr |
· ´ëÇ¥Á¦Ç° | ³ëº¸¼¼ºì¢ç¾ËƼÁÖ´Â 30³â°£ÀÇ ¿¬±¸¿Í ¿ì¼öÇÑ ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» ¹ÙÅÁÀ¸·Î ´Ù¸¥ ÁöÇ÷Á¦¿¡ ºñÇØ º¸´Ù ¸¹Àº ÀûÀÀÁõ¿¡ °ÉÃÄ ÀÓ»óÀû °æÇèÀ» °¡Áö°í ÀÖ½À´Ï´Ù. |
---|---|
· ȸ»ç¼Ò°³ | ³ëº¸³ëµð½ºÅ©´Â Ç÷¿ìº´ÀÇ º¯È¸¦ À§ÇØ ³ë·ÂÇØ ¿Ô½À´Ï´Ù. ¿ì¸®ÀÇ ÁÖ¿ä ¹Ì¼ÇÀº Ç÷¿ìº´ ¹× ÃâÇ÷·Î ¾î·Á¿òÀ» °Þ´Â »ç¶÷µéÀ» À§ÇØ È¿°úÀûÀÌ°í ¾ÈÀüÇÑ Ä¡·áÁ¦¸¦ ¹ß±¼ÇÏ¿© °³¹ßÇÏ´Â °ÍÀÔ´Ï´Ù.
±×·¯³ª, Ç÷¿ìº´À» ÁøÁ¤À¸·Î ¹Ù²Ù·Á¸é ¿Ã¹Ù¸¥ ¾àÀ» °ø±ÞÇÏ´Â °Í ÀÌ»óÀÇ ÀÏÀ» ÀÏÇØ¾ß ÇÑ´Ù´Â °ÍÀ» ¿ì¸®´Â Àß ¾Ë°í ÀÖ½À´Ï´Ù. ³ëº¸³ëµð½ºÅ©´Â ±Û·Î¹ú ÆÄÆ®³Êµé°ú Çù·ÂÇÏ¿© Áø´Ü°ú ´ÙºÐ¾ß Ä¡·á¿¡ ´ëÇÑ ´õ ³ªÀº °á°ú¸¦ ¸¸µé¾î³»±â À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. Changing HaemophiliaTM´Â Ç÷¿ìº´ÀÇ ÃæÁ·µÇÁö ¾ÊÀº ȯÀÚµéÀÇ ¿ä±¸¸¦ ÇØ°áÇϱâ À§ÇÑ ¿ì¸®ÀÇ ¾à¼ÓÀÔ´Ï´Ù. |
· ´ëÇ¥Á¦Ç° | ¾ÆÀ̺ñ±Û·ÎºÒ¸°¿¡½º¿£ÁÖ 10% : ±¹³» ÃÖÃÊ °í¿ë·®, °íÇÔ·® ¸é¿ª±Û·ÎºÒ¸° ÁÖ»çÁ¦·Î½á ȯÀÚ¿¡°Ô ¾ÈÀü¼ºÀ» ³ôÀ̰í ÀÇ·áÁø¿¡°Ô ÆíÀǼºÀ» Á¦°øÇÏ´Â »õ·Î¿î ÆÐ·¯´ÙÀÓÀÇ ¸é¿ª±Û·ÎºÒ¸° ÁÖ»çÀÔ´Ï´Ù. |
---|---|
· ȸ»ç¼Ò°³ | ½Å¾à °³¹ßÀº ¾î·Á¿î ÀÏÀÌÁö¸¸ ȯ¿ìµé¿¡°Ô ²À ÇÊ¿äÇÑ ÀÏÀ̱⿡ GC³ì½ÊÀÚ´Â ±¹³»¸¦ ³Ñ¾î ±Û·Î¹ú °Ç°»ê¾÷ÀÇ ¸®´õ·Î ±× ÀÚ¸®¸¦ ÁöÄѰ¥ °ÍÀ» »ç¸íÀ¸·Î ¿©±â°í ÀηùÀÇ °Ç°ÇÑ »îÀ» À§ÇØ À§´ëÇÑ µµÀüÀ» ¸ØÃßÁö ¾Ê´Â ±â¾÷ÀÌ µÇ°Ú½À´Ï´Ù. |
· ´ëÇ¥Á¦Ç° |
1) ´ºÆ®·ÎÁø: Lenograstim ¼ººÐÀÇ ¿À¸®Áö³Î G-CSF·Î Ç×¾ÏÈÇпä¹ýÀ¸·Î ÀÎÇÑ È£Áß±¸°¨¼ÒÁõ ¿¹¹æ/Ä¡·á ¹× ¸»ÃÊÇ÷Á¶Ç÷¸ð¼¼Æ÷ °¡µ¿È¿¡ »ç¿ëµË´Ï´Ù. 2) Ç𸮺ê¶ó: Ç÷¾×ÀÀ°í Á¦VIII ÀÎÀÚ°¡ °áÇÌµÈ AÇü Ç÷¿ìº´ Ä¡·áÁ¦·Î Ç÷¿ìº´ ȯÀڵ鿡°Ô »õ·Î¿î »îÀ» ¿¾îµå¸± ¼ö ÀÖµµ·Ï ³ë·ÂÇϰڽÀ´Ï´Ù. |
---|---|
· ȸ»ç¼Ò°³ | JWÁß¿ÜÁ¦¾àÀº ÀηùÀÇ °Ç°ÇÑ »îÀ» Áö¿øÇÏ´Â Çõ½ÅÀûÀÎ ±â¼ú, Á¦Ç° ¼ºñ½º¸¦ »ý»ê, Á¦°øÇÏ¿© ¹à°í °Ç°ÇÑ »çȸ¸¦ ¸¸µå´Âµ¥ ±â¿©ÇÏ°í ½Å·Ú¹Þ´Â È°µ¿À¸·Î °í°´, ÁÖÁÖ, ÀÓÁ÷¿øÀÇ ¸¸Á·°ú ÇູÀ» Ãß±¸Çϰí ÀÖ½À´Ï´Ù.
¾ÕÀ¸·Îµµ, JWÁß¿ÜÁ¦¾àÀº ÀηùÀÇ °Ç°¹®È Çâ»ó¿¡ °øÇåÇÏ´Â ¸ð½ÀÀ» º¸¿©µå¸± ¼ö ÀÖµµ·Ï ³ë·ÂÇϰڽÀ´Ï´Ù. |
· ´ëÇ¥Á¦Ç° |
1) ¾Ïºñ¼Ø (Ç×Áø±ÕÁ¦): Liposomal Amphotericin B 50mg 2) ¾Æ³ª±×·¹ (Ç×ÀÀ°íÁ¦, Ç×Ç÷¼ÒÆÇÁ¦, Ç×Ç÷ÀüÁ¦): anagrelide 0.5mg/1mg |
---|---|
· ȸ»ç¼Ò°³ | '¸ðµÎÀÇ °Ç°°ú ÇູÀ̶ó´Â Å« ²ÞÀ» °¡Áø ¹öµå³ª¹«´Â Áö±Ýµµ ±¹¹Î°ú ÇÔ²² ÀÚ¶ó°í ÀÖ½À´Ï´Ù.'
À¯ÇѾçÇàÀº ½Å·Ú¿Í Á¤Á÷ÀÇ ±â¾÷¹®È¸¦ °¡Áö°í ¿ì¼öÇÑ ÀǾàǰ »ý»ê°ú ±¹¹Îº¸°Ç Çâ»ó¿¡ ¸ÅÁøÇØ ¿Ô½À´Ï´Ù. ±¹³» 1µî Á¦¾à»ç, ±¹³» ´ëÇ¥ Àå¼ö±â¾÷ µî ¿ÜÇüÀû ¼ºÀå»Ó¸¸ ¾Æ´Ï¶ó Çѱ¹¿¡¼ °¡Àå Á¸°æ¹Þ´Â ±â¾÷ µî »çȸ°øÇå ´ëÇ¥±â¾÷À¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖÀ¸¸ç, ²÷ÀÓ¾ø´Â ¿¬±¸°³¹ßÀ» ÅëÇØ Çõ½ÅÀû ½Å¾à°³¹ß·Î ±Û·Î¹ú ½ÃÀå ÁøÃâ¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ±¹³» 1µîÀ» ³Ñ¾î ±Û·Î¹ú Á¦¾à»ç·ÎÀÇ ±æ, Àηù °Ç°À» À§ÇÑ ±× ±æÀ» À¯ÇѾçÇàÀº Å« ²ÞÀ» °®°í °É¾î°¡·Á°í ÇÕ´Ï´Ù. |
· ´ëÇ¥Á¦Ç° | ·ÕÄü½º´Â ¼¼Æ÷µ¶¼º ÈÇпä¹ýÀ» Åõ¿© ¹Þ´Â ¾ÏȯÀÚÀÇ ¹ß¿¼º È£Áß±¸°¨¼ÒÁõÀÇ ¹ß»ý°ú ÁßÁõ È£Áß±¸°¨¼ÒÁõÀÇ ¹ßÇö ±â°£À» °¨¼Ò½ÃŰ´Â Ä¡·áÁ¦ ÀÔ´Ï´Ù. |
---|---|
· ȸ»ç¼Ò°³ | Çѵ¶Å×¹Ù´Â ±Û·Î¹ú top10 Á¦¾à»çÀÎ Å×¹Ù¿Í ±¹³» 60³â ÀüÅëÀÇ Çѵ¶ÀÌ °øµ¿ÅõÀÚÇÏ¿© ¼³¸³ÇÑ ÇÕÀÛȸ»ç·Î "º¸´Ù ¸¹Àº ȯÀÚ¿¡°Ô º¸´Ù ¸¹Àº ÇýÅÃÀ» ÁØ´Ù"´Â ºñÀüÀ» ½ÇõÇϱâ À§ÇØ, ¾Ï¼º ÅëÁõ Ä¡·áÁ¦ ÆæÅä¶ó, È£Áß±¸°¨¼ÒÁõ Ä¡·áÁ¦ ·ÕÄü½º, ÆÄŲ½¼º´ Ä¡·áÁ¦ ¾ÆÁú·ºÆ® µîÀÇ Specialty Á¦Ç°°ú ´Ù¼öÀÇ Á¦³×¸¯À» °ø±ÞÇϰí ÀÖ½À´Ï´Ù. |
· ´ëÇ¥Á¦Ç° |
º¥Å¬·º½ºÅ¸¢çÁ¤ (Venclexta)Àº BCL-2 ´Ü¹éÁú¿¡ ¼±ÅÃÀûÀ¸·Î °áÇÕÇÏ¿© ¾ïÁ¦ÇÏ´Â ±âÀüÀÇ ÃÖÃÊ Çã°¡µÈ Ä¡·áÁ¦·Î, ÀÌÀü¿¡ Àû¾îµµ ÇϳªÀÇ Ä¡·á¸¦ ¹ÞÀº ¸¸¼º ¸²ÇÁ±¸¼º ¹éÇ÷º´ ¼ºÀΠȯÀÚ¿¡¼ ¸®Åö½Ã¸¿°úÀÇ º´¿ë ¿ä¹ý°ú ÈÇи鿪¿ä¹ý ¹× B ¼¼Æ÷ ¼ö¿ëü °æ·Î ÀúÇØÁ¦¿¡ Àç¹ß ¶Ç´Â ºÒÀÀÀÎ ¸¸¼º ¸²ÇÁ±¸¼º ¹éÇ÷º´ ¼ºÀΠȯÀÚ¿¡¼ ´Üµ¶ ¿ä¹ýÀ¸·Î ±¹³» Çã°¡µÇ¾ú½À´Ï´Ù. 2020³â 4¿ù 1ÀϺÎÅÍ ÈÇпä¹ý ¹× B¼¼Æ÷ ¼ö¿ëü °æ·Î ÀúÇØÁ¦¿¡ Àç¹ß ¶Ç´Â ºÒÀÀÀÎ ¸¸¼º ¸²ÇÁ±¸¼º ¹éÇ÷º´ ȯÀÚÀÇ 3Â÷ Ä¡·áÁ¦·Î º¸Çè±Þ¿©°¡ ÀÎÁ¤µÇ°í ÀÖ½À´Ï´Ù. |
---|---|
· ȸ»ç¼Ò°³ | ¾Öºêºñ (Abbvie)ÀÇ »ç¸íÀº ÇöÀçÀÇ ½É°¢ÇÑ °Ç°¹®Á¦¸¦ ÇØ°áÇÏ°í ¹Ì·¡¿¡ ¹ß»ýÇÒ ÀÇ·áºÐ¾ßÀÇ µµÀüÀ» À̰ܳ¾ Çõ½ÅÀûÀÎ ÀǾàǰÀ» ¹ß°ßÇϰí Á¦°øÇÏ´Â °ÍÀÔ´Ï´Ù. ´ç»ç´Â ¸é¿ªÇÐ, Á¾¾çÇÐ, ½Å°æ°úÇÐ, ¾È°úÇÐ, ¹ÙÀÌ·¯½ºÇÐ, ¿©¼º°Ç°, ¼Òȱ⳻°úÀÇ ÁßÁ¡ Ä¡·áºÐ¾ß¿Í ¿¤·¯°£ ¿¡½ºÅׯ½ Æ÷Æ®Æú¸®¿ÀÀÇ Á¦Ç°°ú ¼ºñ½º¸¦ ÅëÇØ »ç¶÷µéÀÇ »î¿¡ ÁÖ¸ñÇÒ ¸¸ÇÑ º¯È¸¦ ¸¸µé±â À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ´ç»ç¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ ³»¿ëÀºwww.abbvie.co.kr¿¡¼ È®ÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù.
¾Öºêºñ Á¾¾çÇÐ »ç¾÷ÀÇ ¸ñÇ¥´Â ¾Ï Ä¡·á ¹× ȯÀÚÀÇ Ä¡·á °á°ú¸¦ Çõ½ÅÀûÀ¸·Î °³¼±ÇÒ Ä¡·áÁ¦¸¦ Á¦°øÇÏ´Â °ÍÀÔ´Ï´Ù. 20°¡Áö ´Ù¸¥ Á¾¾ç¿¡ ´ëÇØ ´Ù¼ö,ÀÇ ½Å¾à Èĺ¸ ¹°ÁúµéÀÌ Àü¼¼°è¿¡¼ ÁøÇà ÁßÀÎ ¾à 200°³ÀÇ ÀÓ»ó ½ÃÇèÀ» ÅëÇØ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. ¾Öºêºñ Á¾¾çÇп¡ °üÇÑ º¸´Ù ÀÚ¼¼ÇÑ Á¤º¸´Â http://abbvieoncology.com¿¡¼ È®ÀÎÇÒ ¼ö ÀÖ½À´Ï´Ù. |
· ´ëÇ¥Á¦Ç° |
---|
· ȸ»ç¼Ò°³ |
We provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.
We aim to contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs. In particular, we strive to be a global pharma innovator with competitive advantage in oncology. |
---|
· ´ëÇ¥Á¦Ç° |
Alprolix/Eloctate Ç÷¾×ÀÀ°íÀÎÀÚ 9ÀÎÀÚ(8ÀÎÀÚ)ÀÇ ¹Ý°¨±â°¡ ¿¬ÀåµÈ À¯ÀüÀÚÀçÁ¶ÇÕ Ç÷¿ìº´Ä¡·áÁ¦ Thymoglobulin Àç»ýºÒ·®¼º ºóÇ÷¿¡¼ÀÇ ¸é¿ª¾ïÁ¦¿ä¹ýÁ¦ MOZOBIL ÀÚ°¡Á¶Ç÷¸ð¼¼Æ÷ÀÌ½Ä ¹× äÁý½Ã Á¶Ç÷¸ð¼¼Æ÷ÀÇ °¡µ¿È ÁõÁøÁ¦ |
---|---|
· ȸ»ç¼Ò°³ |
ÇÁ¶û½º ÆÄ¸®¿¡ º»»ç¸¦ µÐ »ç³ëÇÇ ±×·ìÀº Àü ¼¼°è 100¿©°³±¹ 10¸¸ ¸í ÀÌ»óÀÇ Á÷¿øÀÌ ÇÔ²² ÇÏ´Â ¼¼°è ¼±µÎÀÇ ÇコÄÉ¾î ±â¾÷À¸·Î, Àΰ£ÀÇ »îÀ» °³¼±ÇÒ ¼ö ÀÖ´Â Ä¡·á ¼Ö·ç¼ÇÀ» °³¹ß ¹× °ø±ÞÇÏ´Â »ý¸í°úÇÐ ¸®´õ·Î °Åµì³ª°í ÀÖ½À´Ï´Ù. »ç³ëÇÇ´Â »ç¶÷µéÀÌ ÀÏ»ý µ¿¾È °Þ°Ô µÇ´Â ÁúȯÀ» ¿¹¹æÇϰí Ä¡·áÇϱâ À§ÇØ ¿Á¤À» ½ñ°í ÀÖÀ¸¸ç, Áö¿ª»çȸ¿Í ȯÀÚÀÇ °Ç°À» À§ÇØ Çõ½ÅÀûÀÎ °úÇÐ ±â¼úÀ» Á¢¸ñÇÑ »õ·Î¿î ¼Ö·ç¼Ç °³¹ß¿¡ Çå½ÅÇϰí ÀÖ½À´Ï´Ù.
»ç³ëÇÇ´Â ÀǾàǰÀ» ÅëÇØ, ¸¸¼ºÀûÀ̸ç, º¹ÀâÇϰí Èñ±ÍÇÑ ÁúȯÀ» Ä¡·áÇÔÀ¸·Î½á ȯÀÚ¿Í ¹Ì·¡ÀÇ ÇコÄÉ¾î »ê¾÷¿¡ Èñ¸ÁÀ» ÁÙ ¼ö ÀÖ´Â ±æÀ» ¸ð»öÇϰí ÀÖ½À´Ï´Ù. |
· ´ëÇ¥Á¦Ç° |
SPRYCEL¢ç (dasatinib) is a prescription medicine used to treat: Adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). Adults with Ph+ CML who no longer benefit from, or did not tolerate, other treatment, including Gleevec¢ç (imatinib mesylate). Children 1 year of age and older with Ph+ CML in chronic phase
REVLIMID¢ç (lenalidomide) is a prescription medicine, used to treat adults with multiple myeloma (MM) in combination with the medicine dexamethasone, or as maintenance treatment after autologous hematopoietic stem cell transplantation. |
---|---|
· ȸ»ç¼Ò°³ |
At Bristol Myers Squibb, we are inspired by a single vision - transforming patients¡¯ lives through science.
We are in the business of breakthroughs - the kind that transform patients' lives through life-saving, innovative medicines. We have the most talented people in the industry who come to work every day dedicated to our mission of discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. (Celgene is a Bristol-Myers Squibb company) |
· ´ëÇ¥Á¦Ç° |
±×¶ó½Å/±×¶ó½Å 300 ÇÁ¸®Çʵå½Ã¸°ÁöÁÖ´Â ±â¸°¸ÆÁÖ(ÁÖ)°¡ °³¹ßÇÑ »ç¶÷ÀÇ ÇÊ±×¶ó½ºÆÀ(À¯ÀüÀÚÀçÁ¶ÇÕ)À» ÇÔÀ¯Çϴ ȣÁß±¸ °¨¼ÒÁõÀÇ Ä¡·áÁ¦ÀÔ´Ï´Ù. ÇÊ±×¶ó½ºÆÀ(À¯ÀüÀÚ ÀçÁ¶ÇÕ)Àº DNA ±â¼úÀ» ÀÀ¿ëÇÏ¿© Á¦Á¶ÇÑ »ç¶÷ÀÇ °ú¸³±¸ ÄݷδÏÇü¼º ÀÚ±ØÀÎÀÚ(C-CSF: Granulocyte - Colony Stimulating Factor)·Î½á »ç¶÷¹æ±¤¾Ï¼¼Æ÷ÀÇ ¹è¾ç¾× »óÃþÀ¸·ÎºÎÅÍ Á¤Á¦ÇÑ G-CSF¿Í µ¿µîÇÑ »ý¹°ÇÐÀû Ȱ¼ºÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÇÊ±×¶ó½ºÆÀ(À¯ÀüÀÚ ÀçÁ¶ÇÕ)Àº È£Áß±¸ Àü±¸¼¼Æ÷¿¡ ÀÛ¿ëÇÏ¿© ºÐÈ ¹× Áõ½ÄÀ» ÃËÁø½ÃÅ´°ú. µ¿½Ã¿¡ °ñ¼ö·ÎºÎÅÍ ¼º¼÷È£Áß±¸ÀÇ ¹æÃâÀ» ÃËÁø½ÃŰ°í ¼º¼÷È£Áß±¸ÀÇ ±â´Éµµ Ç×Áø½Ãŵ´Ï´Ù.
|
---|---|
· ȸ»ç¼Ò°³ |
Çѱ¹Äì¿Í±â¸°: Äì¿Í±â¸°±×·ìÀº "»ý¸í°úÇбâ¼ú"À» ±â¹ÝÀ¸·Î Áøº¸Àû ±â¼ú°ú »õ·Î¿î °¡Ä¡ÀÇ Ã¢Á¶¸¦ ÅëÇØ ´Ù¾çÇÑ °í°´ÀÇ ¿ä±¸¸¦ ¸¸Á·½Ã۱â À§ÇØ °íǰÁúÀÇ Á¦Ç°°ú ¼ºñ½º¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. Çѱ¹Äì¿Í±â¸°Àº Äì¿Í±â¸°±×·ìÀÇ Çѱ¹ ¹ýÀÎÀ¸·Î 1991³â ⸳ ÀÌÈÄ ¾Ï¡¤½ÅÀå ¹× ¸é¿ªÁúȯºÐ¾ß¿¡¼ ¼¼°èÀû Àü¹®ÀǾàǰ ȸ»ç(Global Specialty Pharma)¸¦ Ãß±¸ÇØ¿À¸ç, Ç×¾ÏÄ¡·á, Ç÷¾×Åõ¼® ±×¸®°í Á¶Ç÷¸ð¼¼Æ÷À̽ÄÀÌ ÇÊ¿äÇÑ ³Ä¡¼º ȯÀÚÀÇ »îÀÇ Áú Çâ»ó°ú »ý¸í¿¬ÀåÀ» À§ÇØ Áö¼ÓÀûÀ¸·Î ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.
Çѱ¹Äì¿Í±â¸°Àº Á¤Á÷(INTEGRITY)À» ±â¾÷ÀÇ Á߿䰡ġ Áß Çϳª·Î »ï°í À±¸®°æ¿µ¼±Æ÷¸¦ ÅëÇØ Åõ¸íÇÑ °æ¿µÀ» ´ÙÁüÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾ö°ÝÇÑ À±¸®±âÁØÀ» Àû¿ëÇÏ¿© ÀÓÁ÷¿øÀÇ ¹ýÀû, À±¸®Àû ÀÇ½Ä °íÃ븦 À§ÇØ ³ë·ÂÇÏ´Â °ÍÀº ¹°·Ð, °í°´°ú ȯÀڷκÎÅÍ ½Å·Ú¸¦ ¾ò´Â ±â¾÷ÀÌ µÉ ¼ö ÀÖµµ·Ï ºÎ´ÜÇÑ ³ë·ÂÀ» °æÁÖÇϰí ÀÖ½À´Ï´Ù. Çѱ¹Äì¿Í±â¸°Àº »çȸÀû Ã¥ÀÓÀ» ´ÙÇÏ´Â ±â¾÷À¸·Î °Åµì³ª±â À§ÇØ ´Ù¾çÇÑ »çȸ°øÇå ÇÁ·Î±×·¥À» ¿î¿µÇϰí ÀÖ½À´Ï´Ù. À̴ ȯÀÚ¿Í ±× °¡Á·À» ºñ·ÔÇÏ¿© ÀÇ·á°ü°èÀÚ ±×¸®°í ±¹¹ÎÀÇ ±â´ë¿¡ ºÎÀÀÇÏ´Â µ¿½Ã¿¡ ±Û·Î¹úÁ¦¾à±â¾÷À¸·Î¼ÀÇ Ã¥ÀÓ°ú Àǹ«¸¦ ´ÙÇϰíÀÚ ÇÏ´Â ¿°¿øÀÌ ±êµé¾î ÀÖ½À´Ï´Ù. "´Ü ÇÑ ¹ø»ÓÀÎ »ý¸í°ú ÇÔ²² °È´Â´Ù."´Â »ý¸íÁ¸ÁßÀÇ Á¤½ÅÀ» ¹ÙÅÁÀ¸·Î Çõ½ÅÀûÀÎ ÀǾàǰ °ø±ÞÀº ¹°·Ð, ½Å¾à°³¹ßÀ» À§ÇÑ ¿¬±¸°³¹ß°ú ÀÎÀç ¾ç¼ºÀ» À§ÇØ ´Ù°¢ÀûÀ¸·Î ±â¿©Çϰí ÀÖ½À´Ï´Ù. Àü ÀÓÁ÷¿ø °³°³ÀÎÀÇ ÈûÀ» °áÇÕÇÏ¿© Àü ¼¼°èÀÎÀÇ °Ç°°ú ¾È³ç¿¡ Áö¼ÓÀûÀ¸·Î ±â¿©ÇϰڽÀ´Ï´Ù. Á¦ÀϾàǰ: 1959³â¿¡ ⸳ÇÑ Á¦ÀϾàǰÀº Àü¹®ÀǾàǰ ºÎ¹®¿¡¼ ¼Òȱâ, ¼øÈ¯±â, ³»ºÐºñ, Á¤½Å½Å°æ¿ëÁ¦, Ç×»ýÁ¦ ºñ·ÔÇÑ Ç×¾ÏÁ¦ ºÐ¾ß¿¡ À̸£´Â Æø³ÐÀº Á¦Ç°±ºÀ» °³¹ß/°ø±ÞÇÏ¿©, ȯÀںеéÀÇ »îÀÇ ÁúÀ» ³ôÀÌ´Â ÀÏ¿¡ °øÇåÀ» ÇØ¿Ô½À´Ï´Ù. ¶ÇÇÑ, ÇØ¿Ü½ÃÀå¿¡¼µµ ¿ø·á ¹× ¿ÏÁ¦ÀǾàǰÀ» 50¿© ±¹°¡¿¡ ¼öÃâÇϰí ÀÖÀ¸¸ç, Çõ½ÅÀûÀÎ ½Å¾à ¹× °³·®½Å¾à °³¹ß¿¡ ¿ª·®À» ÁýÁßÇÏ¿© ±Û·Î¹ú ȯ°æ¿¡¼ °æÀïÇÒ ¼ö ÀÖ´Â ±â¾÷À¸·Î ¼ºÀåÇØ°¡°í ÀÖ½À´Ï´Ù. |
· ´ëÇ¥Á¦Ç° |
<¾ÆÀÌŬ·ç½Ã±×¢çÁ¤>
´Ù¸¥ Ƽ·Î½Å Ű³ªÁ¦ ¾ïÁ¦Á¦ (TKI)·Î Ä¡·áµÇÁö ¾Ê´Â ¸¸¼º±â, °¡¼Ó±â, ±Þ¼º±â ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´ (CML) ¶Ç´Â Çʶóµ¨ÇÇ¾Æ ¿°»öü ¾ç¼º ±Þ¼º ¸²ÇÁ±¸¼º ¹éÇ÷º´ (Ph+ ALL) ¼ºÀΠȯÀÚÀÇ Ä¡·á¿¡ »ç¿ëµÇ´Â 3¼¼´ë TKIÁ¦Á¦ ÀÔ´Ï´Ù. |
---|---|
· ȸ»ç¼Ò°³ |
Çѱ¹¿ÀÃ÷Ä«Á¦¾àÀº ¡®Çѱ¹ÀÎÀÇ °Ç°ÇÑ »î¿¡ °øÇåÇϴ ȸ»ç¡¯¶ó´Â ¹Ì¼ÇÀ» ¹ÙÅÁÀ¸·Î Áúº´ÀÇ Ä¡·á»Ó ¾Æ´Ï¶ó ÀÏ»óÀÇ °Ç° À¯Áö ¹× ÁõÁø¿¡ ±â¿©ÇÒ ¼ö ÀÖ´Â ¿ì¼öÇϰí Çõ½ÅÀûÀÎ ÀǾàǰ°ú ÇコÄɾî Á¦Ç°À» °ø±ÞÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±¹³»¿¡ ´ë±Ô¸ð »ý»ê½Ã¼³À» °®Ãß°í Áö¼ÓÀûÀÎ ¼³ºñÅõÀÚ·Î ±Û·Î¹ú »ý»ê°æÀï·ÂÀ» È®º¸ÇØ ±¹³» °ø±Þ»Ó ¾Æ´Ï¶ó ¿ÀÃ÷Ä«Á¦¾àÀÇ »ý»ê°ÅÁ¡ °øÀåÀ¸·Î¼ÀÇ ¿ªÇÒÀ» È®´ëÇÏ¸ç ¼öÃâÀ» ÅëÇØ Çѱ¹ÀÇ °í¿ë âÃâ ¹× ±¹°¡°æÁ¦¹ßÀü¿¡µµ ±â¿©Çϰí ÀÖÀ¸¸ç, ±Û·Î¹ú Àӻ󿬱¸°³¹ß Ȱµ¿¿¡ Âü¿©, ¿ì¸®³ª¶óÀÇ ÀÓ»ó ¼öÁØ Çâ»ó°ú ½ÃÀåÈ®´ë¿¡ ¾ÕÀå¼¸ç ¿ì¼öÇÑ ½Å¾àÀ» ½Å¼ÓÈ÷ µµÀÔÇϰí ÀÖ½À´Ï´Ù.
|
· ´ëÇ¥Á¦Ç° |
ÀÚÄ«ºñ´Â Áß°£À§Ç豺 ÀÌ»óÀÇ °ñ¼ö¼¶À¯Áõ, È÷µå·Ï½Ã¿ì·¹¾Æ¿¡ ³»¼º ¶Ç´Â ºÒ³»¼ºÀÎ Áø¼ºÀûÇ÷±¸Áõ°¡ÁõÀÇ Ä¡·á ¾àÁ¦·Î¼, COMFORT I,II ¿¬±¸¿¡¼ Áß°£À§Ç豺-2 ÀÌ»óÀÇ °ñ¼ö¼¶À¯Áõ¿¡¼ Àüü»ýÁ¸±â°£ °³¼±À» ÀÔÁõÇÏ¿´½À´Ï´Ù.
|
---|---|
· ȸ»ç¼Ò°³ |
¼¼°èÀûÀÎ Á¦¾à·¹ÙÀÌ¿À±â¾÷, ³ë¹ÙƼ½ºÀÇ ÀÚȸ»çÀÎ Çѱ¹³ë¹ÙƼ½º(www.novartis.co.kr)´Â °è¿»çÀÎ Çѱ¹»êµµ½º¸¦ Æ÷ÇÔÇØ ¾à 580¿© ¸íÀÇ Á÷¿øÀ» µÎ°í ÀÖ´Ù.Çѱ¹³ë¹ÙƼ½º´Â Áö³ 10³â °£ Çѱ¹¿¡¼¸¸ ¾à 200 ¿© °ÇÀÇ ÀÓ»ó½ÃÇèÀ» ÁøÇàÇÏ¿© ±¹³» ¿¬±¸Áø°úÀÇ Çù·ÂÀ» Ȱ¹ßÈ÷ ÁøÇàÇϰí ÀÖÀ¸¸ç, ȯ¿ì ¹× °¡Á· Á¤¼ Áö¿ø ÇÁ·Î±×·¥ÀÎ 'Ä¡À¯(CHEER YOU)', ȯ¿ìÀÇ »çȸ º¹±Í Áö¿ø ÇÁ·Î±×·¥ 'ÀÌÀ½', ¿©¼º ¾ÏȯÀÚ Áö¿ø ÇÁ·Î±×·¥ÀÎ '°¡È¸¾»ç¼º'°ú ¸Å³â Àü Á÷¿øÀÌ ÀÚ¿øºÀ»çȰµ¿¿¡ Âü¿©ÇÏ´Â 'Áö¿ª ºÀ»çÀÇ ³¯' Çà»ç µî ´Ùä·Î¿î »çȸ°øÇåȰµ¿À» ÅëÇØ Áö¿ª »çȸ¿¡ À̹ÙÁöÇÏ´Â ±â¾÷ÀÌ µÇ±â À§ÇØ ÃÖ¼±À» ´ÙÇϰí ÀÖ´Ù.
|
· ´ëÇ¥Á¦Ç° |
¸¿Å×¶ó(Mabthera, ¼ººÐ¸í: ¸®Åö½Ã¸¿)
ÃÖÃÊÀÇ CD20 Ç¥ÀûÄ¡·áÁ¦ ¸¿Å×¶ó ÇÇÇÏÁÖ»ç(MabThera SC, Subcutaneous) 2017³â 1¿ù ¿©Æ÷Çü ¸²ÇÁÁ¾ ¹× ¹Ì¸¸¼º °Å´ë B ¼¼Æ÷ ¸²ÇÁÁ¾ Ä¡·áÁ¦·Î ±¹³» Ãâ½Ã °¡½ÎÀ̹Ù(Gazyva, ¼ººÐ¸í: ¿Àºñ´©ÅõÁÖ¸¿) ÃÖÃÊÀÇ Type 2 ±Û¸®ÄÚ¿£Áö´Ï¾îµå, Àΰ£È ´ÜÀÏŬ·Ð CD20 Ç×ü(Type II glycoengineered, humanized anti-CD20 monoclonal antibody) Æú¶óÀ̺ñ¢ç(Polivy, ¼ººÐ¸í: Æú¶óÅõÁÖ¸¿ º£µµÆ¾) CD79b¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â °è¿ ÃÖÃÊÀÇ Ç×ü-¾à¹° °áÇÕü(antibody-drug conjugate, ADC) |
---|---|
· ȸ»ç¼Ò°³ |
¢ßÇѱ¹·Î½´´Â ¼¼°è 1À§ÀÇ ¹ÙÀÌ¿À Á¦¾à»çÀÎ ·Î½´±×·ìÀÇ Çѱ¹¹ýÀÎÀ¸·Î Áö³ 1983³â ¼³¸³µÇ¾ú´Ù. ±¹³»¿¡´Â ·Î½´±×·ìÀÇ Á¦¾à»ç¾÷ ºÎ¹®ÀÎ ¢ßÇѱ¹·Î½´¿Í Áø´Ü»ç¾÷ ºÎ¹®ÀÎ ¢ßÇѱ¹·Î½´Áø´ÜÀÌ ÀÖ´Ù. Çõ½Å(innovation)À» ÁöÇâÇÏ´Â ·Î½´±×·ìÀÇ Àü·«¿¡ µû¶ó ¢ßÇѱ¹·Î½´´Â Ç×¾ÏÁ¦, ¸é¿ª¾ïÁ¦Á¦, Ç×¹ÙÀÌ·¯½ºÁ¦ µî ´Ù¾çÇÑ ºÐ¾ß¿¡¼ Çõ½Å ÀǾàǰÀ» Á¦°øÇϰí ÀÖÀ¸¸ç, ´Ù±¹Àû ÀÓ»ó½ÃÇèÀ» ±¹³»¿¡ Àû±Ø À¯Ä¡ÇÏ°í ´Ù¾çÇÑ ÀÇÇÐ Æ÷·³À» °³ÃÖÇÏ´Â µî Çѱ¹ ÀÇ·á ȯ°æ ¹ßÀü¿¡ ±â¿©Çϰí ÀÖ´Ù. ¶ÇÇÑ, ¢ßÇѱ¹·Î½´´Â Áö¿ª»çȸ¸¦ À§ÇØ Ã¥ÀÓÀ» ´ÙÇÏ´Â ±â¾÷½Ã¹ÎÀ¸·Î¼ ȯÀÚµéÀÇ »îÀÇ Áú Çâ»ó°ú °Ç°ÇÑ ´ëÇѹα¹À» ¸¸µé±â À§ÇØ ³ë·ÂÇϰí ÀÖ´Ù. ¢ßÇѱ¹·Î½´´Â 2007³âºÎÅÍ ·Î½´±×·ìÀÇ ±Û·Î¹ú »çȸ°øÇåȰµ¿ÀÎ ¡®¾î¸°À̸¦ À§ÇÑ °È±â ´ëȸ(Children¡¯s Walk)¡¯¸¦ °³ÃÖ, Çѱ¹ÀÇ ¼Ò¿ÜµÈ ¾Æµ¿À» µ½°í ÀÖ´Ù. 2012³âºÎÅÍ ¾Ï ȯÀÚµéÀÇ ¿¹¼ú Ȱµ¿ Áö¿ø »çȸ°øÇåÇÁ·Î±×·¥ÀÎ ¡®Èú¸µ°¶·¯¸®(Healing Gallery)¡¯¸¦ ÁøÇàÇØ ¿ÔÀ¸¸ç, 2018³â¿¡´Â NGO ±ÂÇÇÇðú ÇÔ²² ±âÁ¸ÀÇ ¡®Èú¸µ°¶·¯¸®¡¯¿¡ ȯÀÚ¸ÂÃãÇü Áö¿øÀÌ ´õ¿í °ÈµÈ »çȸ°øÇåȰµ¿ÀÎ ¡®Èú¸µÅõ°Ô´õ(Healing Together)¡¯¸¦ ¼±º¸¿´´Ù. ȸ»ç¿¡ °üÇÑ ÀÚ¼¼ÇÑ Á¤º¸´Â ȨÆäÀÌÁö www.roche.co.kr ¿¡¼ È®ÀÎÇÒ ¼ö ÀÖ´Ù.
|
· ´ëÇ¥Á¦Ç° |
º£½ºÆù»ç¢çÁÖ(BESPONSA), º£³×ÇȽº¢çÁÖ(BENEVIX),
ÁøÅ¸¢ç¼Ö·Î½´ÁîÇÁ¸®ÇʵåÁÖ(XYNTHA) |
---|---|
· ȸ»ç¼Ò°³ |
Çѱ¹ÈÀÌÀÚÁ¦¾à¢ß - https://pfizer.co.kr/
|
· ´ëÇ¥Á¦Ç° |
cobas¢ç t 711 / cobas¢ç t 511 coagulation analyzer series´Â Ç÷¾×ÀÀ°í °Ë»çÀÇ ¿ÏÀüÇÑ ÀÚµ¿È¸¦ ±¸ÇöÇÑ Àåºñ·Î½á »õ·Ó°Ô µµÀÔµÈ Ä«¼¼Æ® ŸÀÔ ½Ã¾àÀº Á¤È®¼º°ú ¾ÈÀü¼ºÀº ¹°·Ð °Ë»çÀÇ Ç¥ÁØÈ¸¦ ÀÌ·ï³Â´Ù. ¶ÇÇÑ ºü¸¥ ó¸® ¼Óµµ ¹× »ç¿ëÀÚ Æí¸®¼º °È¸¦ ÅëÇÏ¿© Workflow ÀÇ ±Ø´ëȸ¦ ÀÌ·ï³ÂÀ¸¸ç, ±âÁ¸ Roche ÀÇ °Á¡ÀÎ CCM ÀÚµ¿È ½Ã½ºÅÛ¿¡ ¿¬°áÀ» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á Ç÷¾×ÀÀ°í °Ë»ç¿¡ »õ·Î¿î ÆÐ·¯´ÙÀÓÀ» Á¦½ÃÇÒ »Ó ¾Æ´Ï¶ó, °Ë»çÀÚ ¹× ȯÀÚÀÇ ¿ä±¸¸¦ ÃæÁ·ÇÏ´Â ÀüÀÚµ¿È Ç÷¾×ÀÀ°í°Ë»ç ÅëÇÕ ¼Ö·ç¼ÇÀÌ´Ù. |
---|---|
· ȸ»ç¼Ò°³ | ½ºÀ§½º ÇコÄɾî±×·ìÀÎ ·Î½´ÀÇ Áø´Ü»ç¾÷ºÎ ±¹³»¹ýÀÎÀ¸·Î¼ 1990³â ¿Ü±¹ÀÎ ÅõÀÚ±â¾÷À¸·Î ⸳µÇ¾úÀ¸¸ç Ç÷¾×, ü¾×, Á¶Á÷ µîÀ» °Ë»çÇÏ¿© Áúº´ÀÇ Á¶±â¹ß°ß, ¿¹¹æ, Áø´Ü, Ä¡·á ¹× ¸ð´ÏÅ͸µÀ» À§ÇÑ Çõ½ÅÀûÀÎ Á¦Ç°°ú ¼ºñ½º¸¦ °ø±ÞÇϰí ÀÖ´Ù. Áø´Ü°Ë»ç»ç¾÷ºÎ(Centralized and Point of care Solutions), ºÐÀÚÁø´Ü»ç¾÷ºÎ(Molecular Diagnostics), Á¶Á÷Áø´Ü»ç¾÷ºÎ(Tissue Diagnostics), ´ç´¢°ü¸®»ç¾÷ºÎ(Diabetes Care)ÀÇ 4°³ »ç¾÷º»ºÎ·Î ±¸¼ºµÇ¾î ÀÖÀ¸¸ç º´¿ø ¹× °Ë»ç½ÇÀÇ ´ë¿ë·® ºÐ¼®¿ë ü¿ÜÁø´Ü½Ã½ºÅÛ, »ý¸í°úÇкоßÀÇ ¿¬±¸¿ë ºÐ¼®±â±â ¹× ½Ã¾àÀº ¹°·Ð º´¿øÀÇ ÇöÀå °Ë»ç¿ë ±â±â¿Í Ç÷´çÃøÁ¤±â µî ȯÀÚÀÚ°¡ °Ë»ç±â±â¿¡ À̸£´Â ±¤¹üÀ§ÇÑ Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ °®Ãß°í ÀÖ´Ù. 2019³â ÀÓ»óÀû ÀÇ»ç°áÁ¤ Áö¿ø(Clinical Decision Support, CDS) º»ºÎ¸¦ ÅëÇØ Ŭ¶ó¿ìµå ±â¹ÝÀÇ ÀÓ»ó°áÁ¤ Áö¿ø µ¥ÀÌÅÍ Ç÷§Æû ³×ºñÆÄÀÌ Æ©¸Óº¸µå¸¦ Ãâ½ÃÇÏ¸ç µðÁöÅÐ ÇコÄÉ¾î ¿µ¿ª¿¡ º»°Ý ÁøÃâÇß´Ù. ƯÈ÷, ·Î½´Áø´ÜÀº ·Î½´Á¦¾à°úÀÇ °øÁ¶¸¦ ÅëÇØ °³ÀÎÀÇ À¯ÀüÀû, Á¶Á÷Àû Ư¼ºÀ» Áø´ÜÇØ ÃÖÀûÀÇ Ä¡·á¹ýÀ» ¼±ÅÃÇÒ ¼ö ÀÖµµ·Ï ȯÀÚ¿Í ÀÇ·áÁø ¸ðµÎ¸¦ À§ÇÑ ¸ÂÃãÀÇ·á½Ã´ë¸¦ º»°ÝÀûÀ¸·Î ¿¾î ÀηùÀÇ »îÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖµµ·Ï ³ë·ÂÇϰí ÀÖ´Ù. |
· ´ëÇ¥Á¦Ç° | ÇÁ·¹ºñ¹Ì½º´Â(¼ººÐ¸í : Letermovir) µ¿Á¾ Á¶Ç÷¸ð¼¼Æ÷ À̽ļö¼ú(HSCT)À» ¹ÞÀº ¼ºÀÎ °Å´ë¼¼Æ÷¹ÙÀÌ·¯½º(CMV)-Ç÷û¾ç¼º[R+] ȯÀÚ¿¡ ´ëÇÑ CMV °¨¿° ¹× ÁúȯÀÇ ¿¹¹æ ¾àÁ¦·Î½á 2020³â 9¿ù 1ÀÏ º¸Çè ±Þ¿©¸¦ ¹Þ¾Ò½À´Ï´Ù. |
---|---|
· ȸ»ç¼Ò°³ |
1994³â ¼³¸³µÈ Çѱ¹MSD´Â ȯÀÚ¸¦ ÃÖ¿ì¼±À¸·Î »ý°¢ÇÏ´Â ±â¾÷ Á¤½Å°ú Åõ¸íÇÏ°í ¾ö°ÝÇÑ À±¸® ±âÁØÀ» ¹ÙÅÁÀ¸·Î Çѱ¹»çȸ¿¡¼ ½Å·Ú¹Þ´Â ±â¾÷À¸·Î ¼ºÀåÇØ ¿Ô½À´Ï´Ù. ¾ÕÀ¸·Îµµ Çѱ¹MSD´Â °¡Àå Çõ½ÅÀûÀÎ ÀǾàǰÀ» ºü¸£°Ô ±¹³» ȯÀڵ鿡°Ô ¼Ò°³Çϰí À̸¦ ÇÊ¿ä·Î Çϴ ȯÀڵ鿡°Ô ´õ ³Î¸® Àü´ÞÇϱâ À§ÇÑ ³ë·ÂÀ» Áö¼ÓÇÔÀ¸·Î½á ¡®Çѱ¹¿¡¼ °¡Àå Çõ½ÅÀûÀ̰í Ã¥ÀÓ°¨ ÀÖ´Â ÇコÄÉ¾î ±â¾÷¡¯ÀÌ µÇ±â À§ÇØ ÃÖ¼±À» ´ÙÇÒ °ÍÀÔ´Ï´Ù. |
· ´ëÇ¥Á¦Ç° | µ¥ÇÇÅÚ¸®¿À´Â Á¶Ç÷¸ð¼¼Æ÷ ÀÌ½Ä ÈÄ ¹ß»ýÇÏ´Â ÁßÁõ °£Á¤¸ÆÆó¼âº´ÀÇ Ä¡·áÁ¦ÀÌ´Ù. µ¥ÇÇÅÚ¸®¿ÀÀÇ ÁÖ¼ººÐÀÎ µ¥ÇǺê·ÎŸÀ̵å´Â Ç÷°ü ³»ÇǼ¼Æ÷ÀÇ È°¼ºÀ» °¨¼Ò½ÃÄÑ ¼Õ»óµÈ ³»ÇǼ¼Æ÷¸¦ º¸È£Çϰí, ³»ÇǼ¼Æ÷ ¸Å°³ ÇǺ기 ¿ëÇØÀÛ¿ëÀÇ ±ÕÇüÀ» ȸº¹ÇÏ¿© Ç÷¾× È帧À» °³¼±ÇÑ´Ù. |
---|---|
· ȸ»ç¼Ò°³ | Çѵ¶Àº 1954³â ¼³¸³ ÀÌ·¡ ´ëÇѹα¹À» ´ëÇ¥ÇÏ´Â The Health Innovator·Î ¼ºÀåÇØ¿À°í ÀÖ´Ù. Çѵ¶Àº ¼¼°è À¯¼ö Á¦¾àȸ»çµé°úÀÇ Çù·ÂÇϸç ÀÏÂïÀÌ ±Û·Î¹ú ½ºÅÄ´Ùµå ½Ã½ºÅÛÀ» °®Ãß°í ´ëÇѹα¹ Á¦¾à»ê¾÷ÀÇ ¼±ÁøÈ¸¦ À̲ø¾î¿Ô´Ù. ƯÈ÷, 2012³â ¿À·£ ÇÕÀÛ°ü°è¸¦ Á¤¸®ÇÏ°í µ¶ÀÚ ±â¾÷ÀÌ µÇ¾úÀ¸¸ç 2013³â ÅäÅ»ÇコÄɾî±â¾÷À¸·Î µµ¾àÇϱâ À§ÇØ Çѵ¶¾àǰ¿¡¼ Çѵ¶À¸·Î »ç¸íÀ» º¯°æÇß´Ù. ÇöÀç Çѵ¶Àº Àü¹®ÀǾàǰ, ÀϹÝÀǾàǰ, Áø´Ü½Ã¾à°ú ÀÇ·á±â±â, °Ç°±â´É½Äǰ, Ư¼öÀÇ·á¿ëµµµî½Äǰ µî ´Ù¾çÇÑ ÇコÄɾî Á¦Ç°°ú ¼ºñ½º¸¦ Á¦°øÇϰí ÀÖ´Ù. ¶Ç, ¸ðµÎÀÇ ´õ °Ç°ÇÑ »îÀ» À§ÇØ ¿ÀÇ À̳뺣ÀÌ¼Ç Àü·«À¸·Î °æÀï·ÂÀ» °®Ãá ¿¬±¸°³¹ßÀ» ÆîÃÄ ³ª°¡°í ÀÖÀ¸¸ç Çõ½Å ¹ÙÀÌ¿ÀÀǾàǰ, Ç¥ÀûÇ×¾ÏÁ¦, ÀÇ·á±â±â °³¹ß¿¡ ÁýÁßÇϰí ÀÖ´Ù. |
· ´ëÇ¥Á¦Ç° |
Jamshidi Biopsy needles
¡Ü Trocar Tip Needle ¡Ü Crown Type Cannula ¡Ü The first name in biopsy |
---|---|
· ȸ»ç¼Ò°³ |
For patients and healthcare professionals in wellness and prevention, early diagnosis, treatment, and post-care management. In fact, throughout our history, Bard has lead the industry in groundbreaking devices and therapies that continuously seek to set the new standard for excellence and quality. |
· ´ëÇ¥Á¦Ç° |
¾Öµð³ëº£ÀÌÆ®¢çÁÖ [·ç¸®¿ÁÅäÄÚ±×¾ËÆÄÆä°ñ (Ç÷¾×ÀÀ°íÀÎÀÚVIII, À¯ÀüÀÚÀçÁ¶ÇÕ)]´Â Æä±æÈ(PEGylation) ±â¼úÀ» ÅëÇØ ¹Ý°¨±â¸¦ ¾Öµåº£ÀÌÆ®¢çÁÖ ´ëºñ ¾à1.5¹è ¿¬ÀåÇÏ¿´°í, ¾à¹° Åõ¿© Ƚ¼ö¸¦ ÁÖ 2ȸ·Î ÁÙ¿© ȯÀÚ ¼øÀÀµµ¸¦ ³ôÀÌ¸é¼ ÃâÇ÷À» È¿°úÀûÀ¸·Î ¿¹¹æÇÒ ¼ö ÀÖ½À´Ï´Ù. |
---|---|
· ȸ»ç¼Ò°³ |
Better Health, Brighter Future ´ÙÄÉ´ÙÁ¦¾àÀº Àü ¼¼°è ÀηùÀÇ »îÀÇ Áú Çâ»óÀ» À§ÇØ ´õ ¸¹Àº ÀϵéÀ» ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ °°Àº ¸ñÇ¥¸¦ ÀÌ·ç°íÀÚ ÇÏ´Â ¿Á¤À¸·Î ´ÙÄÉ´ÙÁ¦¾àÀº 1781³â ⸳ ÀÌ·¡ ²ÙÁØÇÏ°Ô Çõ½ÅÀûÀÎ ÀǾàǰÀ» Á¦°øÇØ ¿À°í ÀÖ½À´Ï´Ù. ¿À´Ã³¯ ´ÙÄÉ´ÙÁ¦¾àÀº Áúº´ÀÇ ¿¹¹æ¿¡¼ºÎÅÍ °ü¸®, Ä¡·á¿¡ À̸£±â±îÁö Àü ¼¼°è¿¡ »êÀçÇØ ÀÖ´Â ´Ù¾çÇÑ º¸°Ç ÀÇ·á ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±àÁ¤ÀûÀÎ º¯È¸¦ °¡Á®¿Ã »õ·Î¿î ÇØ´äÀ» ã´Â ÇÑÆí, °¡´ÉÇÑ ÇÑ ¸¹Àº »ç¶÷µé¿¡°Ô ´õ ³ªÀº ÀǾàǰÀ» º¸´Ù ½Å¼ÓÇÏ°Ô Á¦°øÇÑ´Ù´Â ¸ñÇ¥¸¦ Èçµé¸² ¾øÀÌ Ãß±¸Çϰí ÀÖ½À´Ï´Ù. ´ÙÄÉ´ÙÁ¦¾àÀº ±× µ¿¾È ½×¾Æ¿Â Àü¹®¼º, ÁöÇý¿Í °æÇèÀ» ¹ÙÅÁÀ¸·Î ÇコÄɾîÀÇ ¹Ì·¡¸¦ Çâ»ó½Ã۱â À§ÇØ ¾ðÁ¦³ª Çå½ÅÇÒ °ÍÀÔ´Ï´Ù. |
· ´ëÇ¥Á¦Ç° | Blincyto, Kyprolis, Xgeva |
---|---|
· ȸ»ç¼Ò°³ | ¹ÙÀÌ¿ÀÅ×Å©³î·ÎÁö ºÐ¾ß¸¦ ¼±µµÇÏ´Â ¼¼°èÀûÀÎ »ý¸í°øÇÐ Á¦¾à±â¾÷ ¾ÏÁ¨Àº, 2015³â 11¿ù ¾ÏÁ¨ ÄÚ¸®¾Æ¸¦ ¼³¸³ÇÏ°í ½É°¢ÇÑ ÁúȯÀ¸·Î °íÅë¹Þ°í ÀÖ´Â Çѱ¹ ȯÀڵ鿡°Ô ¿ì¼öÇÑ ÀǾàǰÀ» Á¦°øÇϰíÀÚ ÇÕ´Ï´Ù. ¾ÏÁ¨ ÄÚ¸®¾Æ´Â º¸´Ù ¸¹Àº ÀÓ»ó ½ÃÇèÀ» À¯Ä¡Çϰí Çõ½ÅÀûÀÎ ÀǾàǰÀ» °ø±ÞÇÔÀ¸·Î½á ±¹³» ȯÀڵ鿡°Ô Ä¡·á ´ë¾ÈÀ» Á¦½ÃÇÒ °ÍÀÔ´Ï´Ù. ¾ÕÀ¸·Î ¾ÏÁ¨ ÄÚ¸®¾Æ´Â ±¹³» »ý¸í°øÇÐ ¾÷°èÀÇ ÀÏ¿øÀ¸·Î Ȱ¹ßÇÏ°Ô È°µ¿ÇÔÀ¸·Î½á ±¹³» Á¦¾à »ê¾÷ ¹ßÀüÀ» À§ÇØ ±â¿©ÇϰڽÀ´Ï´Ù. |
· ´ëÇ¥Á¦Ç° |
LymphoTrack NGSÀ¯ÀüÀÚÀç¹è¿°Ë»ç LymphoTrackÀº ¸²ÇÁ±¸°è ¾Ç¼º Áúȯ°ú ¾ç¼º ¸²ÇÁ±¸ Áõ½Ä¼º Áúȯ °¨º° ¹× ¹Ì¼¼ÀÜÁ¸Áúȯ È®Àο¡ »ç¿ëÇÒ ¼ö ÀÖ´Â NGS À¯ÀüÀÚÀç¹è¿ °Ë»ç¹ýÀÔ´Ï´Ù. ÃÖ±Ù ½ÅÀÇ·á±â¼ú·Î ÀÎÁ¤µÈ °Ë»ç¹ýÀÔ´Ï´Ù. |
---|---|
· ȸ»ç¼Ò°³ |
´Ù¿ì¹ÙÀÌ¿À¸ÞµðÄ«´Â ü¿ÜÁø´Ü¿ë ÀÇ·á±â±â¸¦ ¼öÀÔ ÆÇ¸ÅÇÏ´Â ¸¶ÄÉÆÃ Àü¹®È¸»çÀÔ´Ï´Ù. ü¿ÜÁø´Ü¿ë ÀÇ·á±â »ê¾÷Àº ±âÃʰúÇаú ÀÇÇÐÀÌ ¸¸³ª´Â ÷´ÜÀÇ À¶º¹ÇÕ ±â¼ú»ê¾÷À¸·Î¼ °¡Àå À¯¸ÁÇÑ ¾÷Á¾À¸·Î ²ÅÈ÷°í ÀÖÀ¸¸ç ¸Å¿ì ¿ªµ¿ÀûÀ¸·Î º¯ÈÇÏ´Â »ê¾÷À̱⵵ ÇÕ´Ï´Ù. ¿ì¸®´Â ÷´ÜÀÇ ±â¼úÀ» º¸À¯ÇÑ ¼¼°èÀû ȸ»çµé°úÀÇ Á¦ÈÞ¸¦ ÅëÇØ ¿¬±¸¿Í ÀÓ»óÁø·á¸¦ ´ã´çÇÏ´Â ¿ì¸® °í°´µé¿¡°Ô ºü¸£°Ô ¼Ò°³ÇÏ°í ¼º½ÇÇÏ°Ô ¼ºñ½ºÇÏ´Â °ÍÀ» Á¦ 1ÀÇ »ç¸íÀ¸·Î ÀÚ°¢Çϰí ÀÖ½À´Ï´Ù. |